Back to Search
JONATHAN GRAFF, MD
MD
Plastic and Reconstructive Surgery Physician
NPI: 1689660508Individual
Specialties, Licenses & Credentials
Surgery of the Hand (Plastic Surgery) Physician
Plastic Surgery — Surgery of the Hand
Code: 2082S0105X
16040101(NY)
Plastic and Reconstructive Surgery PhysicianPrimary
Surgery — Plastic and Reconstructive Surgery
Code: 2086S0122X
16040101(NY)
Research & Publications (20)
eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival.
PMID 19383915·Cancer Res·2009
8-other
Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
PMID 18245460·Cancer Res·2008
6-review
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.
PMID 18156609·J Antimicrob Chemother·2008
4-observational
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.
PMID 17786246·J Clin Invest·2007
7-preclinical
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
PMID 17873238·J Clin Pharmacol·2007
2-rct
Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
PMID 17474542·Int J Clin Pharmacol Ther·2007
4-observational
Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: a double-blind, randomized, parallel-group study.
PMID 17577465·Clin Ther·2007
3-trial
Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.
PMID 17916229·J Thromb Haemost·2007
2-rct
Investigation of the PADA as a method for monitoring GPIIb/IIIa inhibitors and other antiplatelet agents.
PMID 16149028·Semin Thromb Hemost·2005
8-other
Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
PMID 16321613·Clin Pharmacol Ther·2005
3-trial
The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.
PMID 16103100·Cancer Res·2005
7-preclinical
Pharmacodynamic profile of antiplatelet agents: marked differences between single versus costimulation with platelet activators.
PMID 15183041·Thromb Res·2004
4-observational
Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
PMID 12919181·Br J Clin Pharmacol·2003
3-trial
Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs.
PMID 12741684·Clin Exp Metastasis·2003
6-review
Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma.
PMID 11901476·Expert Opin Ther Targets·2002
6-review
Immunosuppressive therapy regimen and platelet activation in renal transplant patients.
PMID 12386643·Clin Pharmacol Ther·2002
4-observational
Close relationship between the platelet activation marker CD62 and the granular release of platelet-derived growth factor.
PMID 11861803·J Pharmacol Exp Ther·2002
8-other
Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
PMID 11422017·Br J Clin Pharmacol·2001
4-observational
Integrin-linked kinase expression increases with prostate tumor grade.
PMID 11448915·Clin Cancer Res·2001
8-other
Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade.
PMID 11751475·Clin Cancer Res·2001
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5611 MAIN ST
WILLIAMSVILLE, NY 14221 - Phone
- (716) 631-8500
Quick Facts
- NPI
- 1689660508
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile